KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
KY-1044  (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256) 纯度: 99.51%

KY-1044 (Alomfilimab; SAR 445256) 是一种针对诱导型共刺激受体 (ICOS) 的全人 IgG1 抗体。KY-1044 在 FcgRIIIa 参与下，通过抗体依赖性细胞毒性 (ADCC) 消耗 ICOS 高的细胞。KY-1044 在表达较低 ICOS 水平的细胞上充当共刺激分子，例如 CD8+ TEff 细胞(通过 FcgR 依赖性聚集)。KY-1044 利用 ICOS 在 T 细胞亚型上的差异表达来改善肿瘤内免疫环境并恢复抗肿瘤免疫反应。

  • KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)
  • KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)

  1. KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)
  2. KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)

CAS No. : 2489390-15-8

规格 价格 是否有货 数量
1 mg ￥3000 In-stock
5 mg ￥7500 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

KY-1044 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].

同型

Human IgG1 kappa
推荐同型对照抗体

Human IgG1 kappa, Isotype Control
种属

Human
体外研究
(In Vitro)

KY-1044 (Alomfilimab; SAR 445256; 0-100ng/mL; 4 小时)导致表达 hICOS (5:1 效应子: 靶细胞比例) 的人类自然杀伤 (NK) 细胞诱导有效的 ADCC 介导的杀伤 (EC50=5.6 pmol/L)[1]。
KY-1044 显着诱导荧光素酶信号 (EC50 为 0.15 nmol/L)，对小鼠 ICOS (0.53 nmol/L)、大鼠 ICOS (0.48 nmol/L) 或食蟹猴 ICOS (0.22 nmol/L) 获得了相似的 EC50[1]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

KY-1044 相关抗体:
体内研究
(In Vivo)

KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; 腹腔注射; 每周两次; 持续 3 周) mIgG2a (效应物启用) 单一疗法可阻断淋巴瘤/骨髓瘤肿瘤模型中的肿瘤生长[1]。
在同基因小鼠肿瘤模型中，KY-1044 耗尽 ICOShigh Treg 并增加瘤内 TEff:Treg 比率，导致 T 分泌 IFNγ 和 TNFα 增加 Eff 细胞[1]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1]
Dosage: 200 μg (10 mg/kg)
Administration: IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation
Result: Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).

Clinical Trial

CAS 号

2489390-15-8
性状

液体

颜色

Colorless to light yellow

中文名称

艾洛利单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • KY-1044 (Synonyms: 艾洛利单抗; Alomfilimab; SAR 445256)
    Human IgG1 kappa
纯度 & 产品资料

纯度: 99.51%

Data Sheet (536 KB) SDS (251 KB)

COA (172 KB)

抗体抑制剂使用指南 (1152 KB)

参考文献

  • [1]. Richard C.A. Sainson, et al. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression. Cancer Immunol Res. 2020 Dec;8(12):1568-1582.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务